Aaron Logan is an Oncology physician affiliated with University of California, San Francisco. OpenAlex indexes 388 publications with 6,943 citations (h-index 39); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
400 Parnassus Ave Fl 4
San Francisco, CA 941432202
Telephone
415-353-2421Registry record last updated 17 Sept 2015.
Clinical trials
- Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)
Sponsor: Jerry Lee, MD, MSc, MPhil
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
27 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year202532 payments$71,762openpaymentsdata.cms.gov ↗
- Servier BioInnovationProgram year20251 payment
- Autolus IncProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
18.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor18.9%Acyclovir100%Part D≥32 patientsAnti-infectives
18.3%Azole Antifungal7.8%Posaconazole79%Fluconazole21%Part D<11 patientsShort-acting sulfonamides3.3%Sulfamethoxazole-Trimethoprim100%Part D≥11 patients+ 3 more classes in this area
Cancer & immunology
18.2%Kinase inhibitor12.6%Iclusig31%Jakafi25%Calquence15%Imbruvica14%Sprycel14%Part D<11 patientsSelective immunosuppressants2%Rezurock100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia
New England Journal of Medicine
2024 - Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2024 - Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL
Journal of Clinical Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Kristine Yaffe, MD
University of California, San Francisco
Peter Carroll, MD
University of California, San Francisco
Mitchel Berger, MD
University of California, San Francisco
Elyse Foster, MD
University of California, San Francisco
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”